Close

Acorda Therapeutics (ACOR) Tops Q2 EPS by 27c

July 31, 2014 8:15 AM EDT

Acorda Therapeutics (NASDAQ: ACOR) reported Q2 EPS of $0.42, $0.27 better than the analyst estimate of $0.15. Revenue for the quarter came in at $97.13 million versus the consensus estimate of $91.4 million.

For earnings history and earnings-related data on Acorda Therapeutics (ACOR) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings

Related Entities

Earnings